Skip to main
OCS

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding is poised for success with its diversified ophthalmology pipeline targeting poorly-served areas of ophthalmic and retinal diseases, including DME, DED, and AON. With positive outcomes in Phase 1 of its DIAMOND and OPTIMIZE-1 clinical trials, the company is confident in the potential of its flagship product OCS-01 for the treatment of DME, which has a peak sales estimate of $1.2 billion in 2035. Additionally, Oculis is also advancing its topical anti-TNF biologic OCS-02 for DED and its neuroprotective agent OCS-05 for AON and other neurodegenerative conditions, each with blockbuster potential if successful. The company also has a strong financial position with pro-forma cash of $292 million, providing runway into 2029.

Bears say

Oculis Holding is a biopharmaceutical company with a negative outlook due to several factors. First, although the completion of the Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema (DME) is a positive development, the reported data will not be available until June 2026. Additionally, there is no guarantee that the trial results will support FDA approval. Furthermore, there are risks associated with the development and regulatory process, as well as the uptake and differentiation of OCS-01 and OCS-02 in their respective indications. These factors could impact the success and market penetration of Oculis Holding's potential products, leading to a negative outlook on its stock.

OCS has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 7 analysts, OCS has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.